Monopar Therapeutics (NASDAQ:MNPR - Free Report) had its price target upped by HC Wainwright from $6.00 to $22.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock.
Separately, Rodman & Renshaw assumed coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They issued a "buy" rating and a $50.00 price target on the stock.
View Our Latest Research Report on Monopar Therapeutics
Monopar Therapeutics Stock Down 1.3 %
NASDAQ MNPR traded down $0.22 during trading hours on Monday, hitting $16.66. 101,823 shares of the stock were exchanged, compared to its average volume of 694,724. The company has a market cap of $65.97 million, a price-to-earnings ratio of -8.46 and a beta of 1.09. Monopar Therapeutics has a 12-month low of $1.37 and a 12-month high of $38.50. The stock has a 50-day moving average of $7.56 and a 200 day moving average of $4.81.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09. On average, equities research analysts expect that Monopar Therapeutics will post -1.93 earnings per share for the current year.
Insider Transactions at Monopar Therapeutics
In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of the firm's stock in a transaction dated Monday, October 28th. The stock was acquired at an average cost of $16.25 per share, with a total value of $25,187.50. Following the acquisition, the chief financial officer now owns 1,550 shares of the company's stock, valued at approximately $25,187.50. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 34.90% of the company's stock.
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
